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ABSTRACT 
 
Purpose: To examine the feasibility of flattening filter free (FFF) volumetric modulated arc therapy 
(VMAT) for extreme hypofractionation of prostate cancer and investigate the potential decrease in 
treatment time per fraction while preserving or improving the treatment quality. To investigate the 
impact of intrafractional prostatic displacement.  
Material and methods: Single arc treatment plans with photon beam qualities 10 MV with flattening 
filter (FF), 6 MV FFF and 10 MV FFF were created for nine patients treated with conventional 
fractionation (78 Gy, 2 Gy/fraction) and hypofractionation (42.7 Gy, 6.1 Gy/fraction), respectively. 
Dose-volume histograms (DVH) for all beam qualities were statistically evaluated using a paired 
sample Student’s t-test. Treatment delivery was evaluated through measurements on a Varian 
TrueBeam™ using a Delta4 PT system (ScandiDos AB). The beam-on time for each plan was 
recorded. A motion study, including one FF and one FFF hypofractionated treatment plan, was also 
performed using the HexaMotion (ScandiDos AB) and with trajectory data from six authentic prostate 
movement patterns.  
Results: All treatment plans were approved by a senior radiation oncologist. Evaluating the DVHs, no 
significant differences between beam qualities or between fractionation schedules were observed. All 
objectives were met for all plans. At the treatment delivery all plans passed the gamma criterion 3%,  
2 mm with a pass rate of 98.8% or higher. The beam-on time for all conventional treatment plans was 
1.0 minute. The mean beam-on time was 2.3 minutes for the hypofractionated 10 MV FF plan,  
1.3 minutes for the 6 MV FFF and 1.0 minute for the 10 MV FFF. In the motion study, no or little 
effect was observed on the pass rate for displacements ≤1mm. The shorter treatment delivery was 
superior for three patterns, while the longer treatment was preferred in the case of temporal 
displacement of the prostate. 
Conclusions: The treatment time for extreme hypofractionation of prostate cancer is reduced to less 
than half the time per fraction by combining FFF-technique with VMAT. The treatment plan quality 
was preserved for the FFF beams. Finally, a shorter beam-on time also seems advantageous for the 
majority of prostate motion patterns investigated. Based on this work, it is feasible to implement FFF 
VMAT for extreme hypofractionation of prostate cancer (HYPO-RT-PC trial) at the radiotherapy 
department at Skåne University Hospital, Lund.  
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Popular scientific summary in Swedish: 
Snabb, säker och strålande – ny teknik vid behandling av prostatacancer 
 
I skrivande stund är sju olika cancercentra i Sverige, däribland Skånes Universitetssjukhus i Lund, 
mitt uppe i en gemensam randomiserad studie som undersöker behandling av prostatacancer med två 
olika strålningsscheman. Patienterna i studien blir slumpvis tilldelade antingen en standardbehandling, 
där de får en liten mängd strålning vid 39 olika tillfällen, eller en så kallad hypofraktionerad 
behandling, där de istället får ca tre gånger så mycket strålning per gång vid endast 7 tillfällen. Målet 
med studien är att testa om den hypofraktionerade behandlingen kan ge ett bättre resultat med ökad bot 
utan högre grad av biverkningar.  
 
Prostatacancer är den vanligaste cancerformen i Sverige och årligen diagnosticeras nära 10 000 män – 
motsvarande ungefär en man i timmen, dygnet runt, året om. Prostatan i sig är en körtel som sitter i 
nedre delen av buken, nära blåsa och ändtarm. Eftersom den inte är fixerad i någon fast struktur 
påverkas prostatans position av bland annat blåsfyllnad, ändtarms-aktivitet och ofrivilliga 
muskelrörelser i underkroppen. Detta innebär att prostatan även har en viss sannolikhet att röra sig 
under pågående strålbehandling, trots att positionen verifieras och, vid behov, justeras genom 
bildtagning innan varje behandling påbörjas. Studier har visat att avvikelsen i prostatans position blir 
större ju längre tid som går, varför många menar på att man bör hålla behandlingstiderna så korta som 
möjligt.  Eftersom det vid hypofraktionering tar längre tid vid varje behandlingstillfälle, då en större 
mängd strålning ska levereras, har syftet med detta examensarbete varit att undersöka hur mycket 
behandlingstiden kan förkortas genom användning av en nyare teknik, så kallad flattening filter free 
(FFF) strålbehandling. Målet var även att säkerställa att de nya behandlingarna kunde planeras och 
levereras med minst lika bra kvalitet som de nuvarande. För detta valdes nio patienter ut från hypo-
studien och jämfördes på sex olika sätt. Slutligen genomfördes en rörelsestudie på en av patienterna, 
där några olika rörelsemönster och deras eventuella inverkan på strålleveransens precision 
undersöktes.  
 
Resultaten visade att genom att kombinera FFF-teknik med den redan befintliga rotations-
behandlingen, kunde tiderna för hypofraktioneringen mer än halveras för samtliga patienter. Efter 
noggrann utvärdering av behandlingsplanerna genererade med FFF, kunde dessa konstateras hålla 
samma höga kvalitet som de med nuvarande teknik. Vidare kunde även en högkvalitativ strålleverans 
säkerställas genom inmätning med kvalitetssäkringsutrustning. Den nya, korta behandlingstiden är 
densamma som för en standardbehandling, samtidigt som tre gånger mer strålning levereras. Med 
hypofraktionering behöver patienten bara behandlas vid 7 tillfällen, jämfört med annars 39, vilket 
gynnar både den individuella patienten men också sjukvården och samhället i stort, sett ur ett 
ekonomiskt perspektiv. Fördelen med att hålla nere tiden visade sig även i rörelsestudien, där en kort 
behandling gav bättre resultat än en lång för alla undersökta rörelsemönster utom ett, men där var 
skillnaden väldigt liten. Det var tydligt att prostatans drift ur position påverkade strålleveransen, även 
inom tidsramen av några få minuter. 
 
Baserat på detta arbete kunde slutsatsen dras att det är möjligt, och dessutom fördelaktigt, att minska 
behandlingstiden för hypofraktionerad strålbehandling av prostatacancer, genom införandet av FFF-
teknik, ner till samma tid som det tar att leverera en standardbehandling. 
 
 
Minna Ahlström 
 
Handledare: Hunor Benedek, Per Nilsson, Tommy Knöös och Crister Ceberg 
Examensarbete (30 hp) i medicinsk strålningsfysik, vårterminen 2015 
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AP Anterior-Posterior  
BED Biological Effective Dose 
CT Computed Tomography 
CTV Clinical Target Volume 
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1 INTRODUCTION 
 
Radiotherapy is a treatment given to about 45-55 % of all cancer patients in Europe (Slotman et al., 
2005). External beam radiotherapy (EBRT) is a non-invasive treatment with the aim to accurately 
deliver a high radiation dose to the tumour while preserving the surrounding normal tissues. Recent 
decades’ of technical and computational evolution has allowed for more advanced treatment 
techniques to become widely available. Since the first medical linear accelerator in 1953, the 
treatments as well as the radiation beams have become increasingly complex (Thariat et al., 2013). In 
the mid 90’s Yu (1995) presented intensity modulated arc therapy (IMAT), a rotational therapy 
continuously modulating the beam, at a fixed dose rate and gantry rotation speed, using several 
overlapping arcs. Otto (2008) further refined this technique and introduced the volumetric modulated 
arc therapy (VMAT) technique, where the aim was to deliver optimized treatment plans with high 
dose conformity in an efficient and accurate way. The VMAT technique allows beam-on during a full 
gantry rotation of 360° with simultaneous modulation of the multileaf collimator (MLC) and a 
variation of gantry rotation speed as well as dose rate. VMAT can be used for treating various types of 
cancer and is for example the most efficient radiotherapy for prostate cancer, delivering high quality 
treatments in the least amount of time (Wolff et al., 2009). 
 
Prostate cancer is the most common type of cancer in Sweden. During 2012 almost 9000 men were 
diagnosed with the disease. In the past 20 years there has been an increasing incidence, mainly due to 
diagnostics using PSA-testing but also as a result of an older population (Cancerfonden, 2014). For 
localized prostate cancer, the disease is divided into three categories; low risk, intermediate risk and 
high risk (Swedish national health care programme for prostate cancer, 2015). The choice of treatment 
is based on the severity of the cancer, with the following options; to monitor the patient with no 
treatment (watchful waiting), surgery or radiation therapy. Some patients are prescribed a combination 
of treatments and others may also receive hormone therapy. According to an evidence based estimate 
from 2003, about 60 % of the prostate cancer patients will require radiotherapy at some point during 
their illness, including palliative treatment (Foroudi et al., 2003). 
 
There is an on-going debate about the radiobiology of prostate cancer, affecting the choice of optimal 
fractionation schedule in the treatment of the cancer where, typically, radiation fraction sizes of 1.8 to 
2.0 Gy have been used as standard (Nahum, 2015). The Biologically Effective Dose (BED) depends 
not only on the total dose (D) given but also on the dose per fraction (d). The model for calculating 
BED is based on the linear quadratic model for cell survival;  = (	
). The ratio α/β quantifies 
the fractionation sensitivity of the tissue. Recent studies imply that the α/β ratio for prostate cancer is 
lower than previously assumed (Williams et al., 2007, Brenner and Hall, 1999), and even lower than 
for late normal tissue complications, which indicates a potential benefit of using hypofractionated 
radiotherapy. If α/β is low, the cancer cells would be more sensitive to large fraction sizes; thus hypo-
fractionation, delivering higher absorbed dose per fraction using fewer fractions, may be favourable.  
 
A current Scandinavian study by Widmark et al. (2014) is investigating this issue. The study is a 
prospective randomized phase III trial (HYPO-RT-PC), which compares extreme hypofractionation 
with conventional fractionation in intermediate risk prostate cancer patients. One of the major 
recruiting trial centres is Skåne University Hospital in Lund (SUS). In the study the patients are 
randomly assigned to a conventional treatment, 78 Gy in 39 fractions (2.0 Gy/fr), or to a hypo-
fractionated treatment, 42.7 Gy in 7 fractions (6.1 Gy/fr). This extreme version of hypofractionation is 
advantageous based on theoretical improvements in outcome, without increasing late toxicity. The 
treatment is delivered via image-guided radiotherapy (IGRT) where daily kilo voltage (kV) set-up 
images or cone beam computed tomography (CBCT) is used to verify the position of the prostate 
based on implanted fiducial markers. In Lund the treatment is delivered using VMAT with daily kV 
set-up images.  
 
As a result of the higher fraction dose of the hypofractionated treatment, each treatment session will 
consequently have a longer duration compared to the conventionally fractionated treatment. The 
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longer the session, the less accurate is the position of the patient (and the prostate gland in particular). 
The prostate gland is not attached to any fixed anatomical structure and could thus move inter- and 
intra-fractionally. Any change in position of the prostate between fractions can be corrected for using 
IGRT. The movement within a fraction is more complex, where any displacement of the prostate 
during treatment is likely to be due to rectal movements, muscle clenching or leg movement 
(Nederveen et al., 2002). The majority of prostate movements are accounted for in the added margin 
when outlining the target prior to the treatment. However, temporary displacements where the prostate 
gland has moved more than 10 mm for part of the fraction have been reported (Padhani et al., 1999). 
This could potentially lead to less dose coverage, especially in the case of hypofractionation. Tong et 
al. (2015) and Ballhausen et al. (2015) have recently emphasised the importance of keeping the 
treatment times to a minimum because of uncertainties due to prostate motion. 
 
A faster radiation delivery can be achieved using flattening filter free (FFF) photon beams. Removing 
the flattening filter allow for a significant increase in dose rate, which ultimately can shorten the 
treatment times (Gasic et al., 2014, Alongi et al., 2013, Dzierma et al., 2014). 
2 AIM 
The purpose of this study was to investigate the potential saving in treatment time for VMAT with 
flattening filter free photon beams in extremely hypofractionated radiotherapy of prostate cancer, and 
especially for the HYPO-RT-PC study. The goal was to decrease the treatment delivery time per 
fraction, while preserving or improving the treatment plan quality. Radiation delivery quality was 
verified through measurements. The analysis was carried out as a treatment planning study on nine 
patients from the HYPO-RT-PC study. Six different treatment plans were designed and evaluated for 
each patient.  
 
A review was also carried out on the currently available literature on prostate motion in order to 
discuss the clinical importance of shortening the treatment session. A motion study was designed for 
six different prostate trajectories (Ng et al., 2012), where the two most extreme treatment plans for a 
selected patient were delivered during motion. The aim was to get an indication of the impact of 
different prostate motion patterns and identify any differences between the treatments with flattened 
and unflattened beams.   
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3 THEORY AND BACKGROUND 
3.1 VMAT 
Volumetric modulated arc therapy (VMAT) is a novel radiotherapy technique. It can typically deliver 
a 2 Gy fraction with high dose conformity to the target while preserving the healthy surrounding 
tissue, all in less than 2 minutes (Palma et al., 2010). The high accuracy of the treatment is achieved 
using inversely optimized treatment planning. Varian Medical System has termed their VMAT 
technique RapidArc®, which entered the market in 2008. In the radiotherapy department at the Skåne 
University Hospital there are currently six Varian TrueBeam™, all equipped with VMAT. The outputs 
of the linacs are matched and verified on a regular basis, providing equivalent treatment deliveries. 
The measurements of this study were carried out on one of the TrueBeams, while the results are 
assumed to be valid for all of them.  
 
The idea behind VMAT is developed from intensity modulated arc therapy. The algorithm optimizing 
the treatment plan allows the dose to be delivered during a full 360° rotation of the gantry. The 
technological requirement is a rotational medical linear accelerator equipped with a dynamic multileaf 
collimator (MLC), the possibility to vary dose rate and a gantry rotation speed that can be adjusted 
accordingly (Otto, 2008). 
 
 
 OPTIMIZATION OF TREATMENT PLANS 
The VMAT optimization algorithm integrates the MLC position and the monitor unit (MU) weight as 
its parameters. In the process, both mechanical and efficiency constraints are applied. The goal 
function that determines the outcome of a performed iteration is based on dose-volume objectives. 
These are defined individually by the user who may put constraints on both upper and lower absorbed 
doses to the tumour as well as upper dose constraints to surrounding organs. Over the iterations the 
goal function is optimized towards its minimum. The duration of the process is determined by a 
defined stopping criteria or by a maximum number of iterations. 
 
VMAT optimization operates on the idea of a finite number of static positions used to simulate the 
dynamic motion. The full arc is divided into ten initial positions, evenly distributed over the range of 
angles. Midway between each of these consecutive samples, a MLC instantaneous configuration is 
modelled and the MU weight is averaged over the covered sub-arc angle range. This is the starting 
position of the inverse optimization process. Using several iterations, both MLC positions and MU 
deliveries are optimized. Next, new sample points are added between each of the ten initial samples as 
the optimization continues (see Figure 1 for illustration). Each time a new sample is introduced, the 
goal function is recalculated. The process is repeated until the desired sampling frequency is reached. 
Unsurprisingly, the higher the sampling frequency, the more accurate the estimation of the delivered 
plan will become (Otto, 2008). 
 
 
Figure 1. (a) The optimization is initially based on a small set of static points.  
(b, c) New sample points are successively added between the already existing control points.  
(d) The process is repeated until the desired frequency of control points is reached. (Otto, 2008) 
 
 10
The VMAT plans in this study were created in the Eclipse treatment planning system (Varian Medical 
Systems, Inc.) using its VMAT optimizer. Different weight factors are set to different structures, based 
on the priorities of the constraints (usually defined in a separate treatment protocol). Objectives can 
also be changed interactively throughout the optimization. The optimization process itself is based on 
the one described above and is a progressive resolution optimization. For VMAT the process is 
divided into 4 multi-resolution (MR) levels, where control points are added in groups instead of one at 
a time. The initial number of control points is 10 and increases at the end of every MR, reaching 178 
control points at MR4.  
 
 DOSE CALCULATION 
For absorbed dose calculations in Eclipse the Anisotropic Analytical Algorithm (AAA) for photons is 
applied. The algorithm is based on a three dimensional pencil beam convolution/superposition with a 
possible grid range of 1-5 mm. The calculation accounts for heterogeneities inside the patient’s body, 
through photon scatter kernels. These are weighted by information from the patient’s CT image sets, 
working both in the beam’s direction as well as perpendicular to it. The configuration of photon beams 
is modelled from separate Monte Carlo simulations for the primary photon beam, scattered photons 
and electrons scattered from the treatment head. The final dose volume is calculated with photon and 
electron convolutions that are super-positioned (Varian Medical Systems, 2011). In this study the 
AAA version 10.0.28 was used with a grid size of 2.5 mm. 
 
The AAA has been shown to produce accurate dose modelling not only for standard photon beams but 
also for FFF beams (Lang et al., 2012). 
 
 
3.2 PLAN COMPLEXITY 
Treatment plans can express different levels of delivery complexity. In this study the complexity is 
measured in monitor units (MU) per unit dose (Gy). A standard open field of 10 cm x 10 cm requires, 
by definition, 100 MU to deliver 1 Gy at the depth of maximum dose and SSD = 100 cm. The 
definition of MU is the same for all beam qualities, allowing relative comparison between energies. 
An open field has no modulation and thus the lowest grade of complexity. A treatment plan that 
requires a larger number of MU to fulfil the dose constraints, for a set prescribed dose, is said to be 
more complex. In general, a plan that is more modulated automatically uses a larger number of MU. 
One reason for this can be contradictory constraints on the defined target and nearby organs at risk 
(OAR). In the case of prostate cancer this can occur because of the requirements on dose coverage of 
the prostate (target) and the request to keep rectum dose to a minimum.   
 
Effectively, the complexity is reflected in the MLC-movement pattern. To deliver a more complex 
plan, the MLC must move more rapidly and the shift in MLC position of individual leafs is likely to 
be larger between two control points. The complexity could also affect the dose rate. If the modulation 
is too complex, the gantry speed is reduced in order to deliver the required dose in a segment. This 
could lead to an increase in treatment time, which contradicts the purpose of VMAT being the most 
efficient treatment technique. Other measures of complexity are also available, but for the purpose of 
this work the concept of MU/Gy was considered sufficient. 
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3.3 HYPOFRACTIONATED RADIOTHERAPY 
During the last decades, conventionally fractionated dose escalation has been a major trend in 
radiotherapy of prostate cancer. It has shown to improve biochemical control without significant 
increase in late toxicity (Hall and Giaccia, 2006). However, recent studies imply that the 
radiobiological properties of the prostate cancer cells are more similar to late-responding normal 
tissues than acutely reacting tissues and several other tumours. This suggests that the tumour control 
could be equally good or improved, without increased toxicity, choosing a treatment schedule with 
fewer but larger fractions (Williams et al., 2007, Brenner and Hall, 1999). Radiotherapy schedules 
using less number of fractions prescribed with a higher dose (>2 Gy) in each fraction are called hypo-
fractionated regimens.  
 
 BIOLOGICALLY EFFECTIVE DOSE AND THE LINEAR-QUADRATIC CONCEPT 
The linear quadratic model is often used to compare different fractionation schedules in a quantitative 
way. Through this model the biological effective dose (BED), as a function of prescribed dose and 
number of fractions, may be calculated. The model also includes a radiobiological constant ( )⁄  
representing the type of radiation damage, acute or late. Acute normal tissue reactions are by 
definition those that appear during treatment or within 90 days after finishing the treatment, while late 
damage appears more than 90 days after finishing the treatment.  
 
The linear quadratic model is based on the cell-survival curve, survival as a function of absorbed dose 
(Figure 2). The curve has an initial slope followed by a shoulder, which depends on the accumulation 
and ability to repair sublethal damage of the cells. No shoulder indicates the lack of ability to repair 
cells. The cell survival at a delivered single dose, D, may thus be expressed as  
 
 = 	                       (1) 
 
where α is the loge of the cells killed per gray (the linear component) and β is the loge of the cells 
killed per gray squared. The cell killing due to the linear and the quadratic components, respectively, 
are equal at dose  = /.  
 
 
 
Figure 2. Graph illustrating the linear-quadratic relation between radiation cell survival, S, and dose, D.  
For densely ionizing radiation the cell survival is an exponential function of the dose, S=exp(-αD). For sparsely 
ionizing radiation, such as x-rays, the curve has an initial slope, followed by a shoulder and includes a linear  
and a quadratic component, S=exp(-αD-βD2). The two components are equal at dose D=α/β. (Chul-Seung and 
Young-Nam, 2013) 
 
 
Dose [Gy] 
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The biological effect of a single fraction of dose, D, is assumed to be proportional to –ln(S) and is 
hence given by 
 =                          (2) 
 
For n fractions of dose d the biological effect may be expressed as  
 
 = (  )                        (3) 
 
assuming the time between fractions is long enough for complete repair of sublethal damage between 
fractions. Finally, biological effective dose (BED) is the quantity of which different fractionation 
regimens are compared. This is expressed as E divided by α and then rearranged, giving  
 
 =  = ()  1  
/	 = (total	dose)  (relative	effectiveness)            (4) 
 
The α/β ratio can be interpreted as a quantification of the fractionation sensitivity of the tissue. A low 
α/β indicates a larger sensitivity to changes in fractionation size and is found in e.g. late-responding 
tissues. Early-responding tissues are often assigned a larger α/β, indicating less sensitivity to 
fractionation changes (Hall and Giaccia, 2006).  
 
The effect of a given treatment schedule can be converted to that of a standard schedule of 2 Gy per 
fraction using the equivalent dose, EQD2. This is derived from the respective BED equations provided 
that α/β is equal in the two regimens. The equivalent dose of the arbitrary schedule then becomes 
 
+2 =  ∙ 
/	/	    (5) 
 
where D is the total dose and d is the fraction dose, both of the arbitrary schedule.  
 
In the HYPO-RT-PC study the standard fractionated treatment delivers a total of 78 Gy in 2 Gy 
fractions to the PTV, whereas the hypofractionated treatment delivers 42.7 Gy in 6.1 Gy fractions. 
Performing the calculation of EQD2 on the schedule of the hypofractionated treatment arm yields the 
following results: 
 
 ⁄ = 3	Gy → +2 = 78	Gy 
 ⁄ = 1.5	Gy → +2 = 93	Gy 
 
Hence, the hypofractionated treatment is equally efficient to the standard treatment if α/β=3 Gy 
(typical α/β ratio for late normal tissue reactions) but is theoretically superior to the standard treatment 
if α/β=1.5 Gy, as recent publications indicate (Dasu and Toma-Dasu, 2012).  
 
 
3.4 FLATTENING FILTER FREE X-RAY BEAMS 
The flattening filter is a standard component in the treatment head of medical linear accelerators. The 
cone-shaped filter flattens the x-ray dose profile and creates a uniform beam (Metcalfe et al., 2007). 
However, as the treatment techniques have become more advanced and modalities such as intensity 
modulated rotational therapy (IMRT) and VMAT have been introduced, the flat beam profile is no 
longer an obvious requirement, and removing the flattening filter may even be favourable in specific 
situations (Stathakis et al., 2009, Gasic et al., 2014). 
 
When removing the flattening filter, the beam characteristics change. The profile of the FFF beam 
becomes conical and has a softer spectrum. The effect of off-axis softening, seen in flattened beams, is 
not as significant in unflattened beams. Due to the reduction of this effect the depth dose 
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characteristics are almost constant throughout the entire field. This is also observed in that the shape of 
the dose profile with depth changes less than for flattened beams (by only a few percentage units) 
(Georg et al., 2011).  Further, there is less head scatter when the flattening filter, being one of the main 
sources of scatter, is removed which might reduce the relative risk of out-of-field secondary 
malignancies (Murray et al., 2015). Finally, the fact that the maximum available dose rate is at least 
double the one in flattened beams is beneficial in reducing the duration of the treatment delivery 
(Dzierma et al., 2014).  
 
 
3.5 DELTA4 AND HEXAMOTION 
The Delta4 pre-treatment verification phantom is a product from ScandiDos AB, Uppsala, Sweden. 
The phantom can be used for verifications of advanced radiotherapy treatment techniques, such as 
VMAT. Studies have shown that the reproducibility of the measurements is high on a day-to-day basis 
as well as for repeated measurements (Korreman et al., 2009). The Delta4 has also been proven equally 
successful for dose evaluation using high dose rate FFF beams in VMAT, where the introduced dose 
difference between high and low dose rates was shown to be negligible (Kalantzis et al., 2012). 
 
The phantom is an acrylic (Polymethylmethacrylate, PMMA) cylinder with two integrated, 
orthogonally positioned, detector planes. Each detector plane has a detection area of 200x200 mm2, 
with a total of 1069 p-type Si detectors. The positioning of the detector elements is particularly dense, 
with a resolution of 5 mm, around the isocenter which allows for accurate measurements of the dose 
distribution in this region, making the phantom a suitable tool for complex plan evaluation.  
 
The Hexamotion is a supplementary module from ScandiDos, which can be used in combination with 
the Delta4 to simulate multi-dimensional realistic movement patterns. A text file describing the 
trajectory of the phantom motion in three dimensions is used as input. The frequency of position 
changes is 50 Hz, with a guaranteed accuracy in position of at least 0.5 mm (ScandiDos AB, Uppsala, 
2012). 
 
 
3.6 DOSE DISTRIBUTIONS AND GAMMA EVALUATION 
The comparison of planned and delivered dose is often analysed with three different methods; distance 
to agreement (DTA), dose deviation and gamma index.   
 
The basic idea of the dose deviation is to calculate the difference between the measured Dm and the 
calculated dose D for every position, r. The dose deviation is most suitable in regions with low dose 
gradients. In areas of high dose gradients a small offset in position may result in large, not necessarily 
relevant, dose deviations. Therefore, in areas of high dose gradients the method of distance-to-
agreement (DTA) is more applicable. This method also compares two dose distributions, but for every 
point in the measured data, the nearest point in the calculated data with the same dose as the measured 
point is identified. The distance between the two points is calculated and defined as the DTA. Both 
methods are supplemented by acceptance criteria set by the user aiming to identify areas of significant 
disagreement. 
 
Gamma evaluation was established by Low et al. (1998) as a numerical quality index for evaluation of 
three-dimensional (3D) treatment planning systems. Their aim was to combine the already existing 
methods of dose deviation and distance to agreement (DTA), and present a more instructive evaluation 
method to display the areas that fail both comparison criteria. 
 
The gamma criterion can be represented by an ellipsoid in a coordinate system representing space and 
dose simultaneously (Figure 3). Assuming that the dose-deviation criterion is defined as ∆8  
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(e.g. 3%) and the DTA criterion is ∆8 (e.g. 2 mm), the gamma acceptance criterion can be defined as 
the ellipsoid surface represented by the two methods simultaneously: 
 
1 = 9:(;<,;)∆
> 
?(;<,;)
∆>      (6) 
 
where the DTA and the dose difference are mathematically described as 
 
@(;A, ;) = |; C ;A|                          (7) 
and 
D(;A, ;) = (;) C A(;A)        (8) 
 
where rm is the position of the measured data point and r is an arbitrary position of comparison.  
 
 
Figure 3. Two-dimensional geometric representation of the ellipsoid representing the combined evaluation of 
dose difference and distance-to-agreement. The measured data point is located at the origin of the coordinate 
system (Low et al., 1998). 
 
The gamma index is identified as the difference in dose distributions between the calculated and the 
measured doses. For each measured point in the evaluation a gamma value is determined for every 
calculated point according to:  
 
Γ(;A, ;F) = 9:(;<,;G)∆
> 
?(;<,;G)
∆>               (9) 
 
where 
@(;A, ;G) = |;G C ;A|    (10) 
and 
D(;A, ;G) = F(;G) C A(;A)          (11) 
 
where rc is the position of the calculated dose, which is to be compared to the measured dose in rm. 
 
The gamma index is defined as the smallest gamma value: 
 
H(;A) = minJK(;A, ;)L ∀J;FL           (12) 
 
The result of the evaluation is determined by the outcome of the gamma index. A point passes the 
gamma criterion if H(;A) N 1, whereas a point fails if H(;A) O 1. 
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3.7 PROSTATE MOTION 
Image guided radiotherapy has reduced the uncertainty of inter-fractional motion of the prostate gland. 
Verification of the prostate position within the pelvis relative to bony structures or through implanted 
markers at the start of each treatment session has improved the outcome of the radiotherapy (Zelefsky 
et al., 2012). However, rectal activity, bladder filling, muscle clenching and pelvis movements, all of 
which may occur during the course of a single treatment fraction, also affect the position of the 
prostate and could potentially induce prostate displacement and changes in prostate shape during the 
treatment fraction (Nederveen et al., 2002). The intra-fractional prostatic motion adds uncertainty to 
the position and must be accounted for in added CTV-PTV margins in order to minimise the risk of 
reduced target coverage. There are numerous studies investigating the issue of prostate displacement, 
using various techniques such as cine MRI, ultrasound, electromagnetic markers, on-line x-ray images 
and continuous monitoring using a radiofrequency tracking system. For this section, some of the 
currently available literature on intra-fractional motion has been selected and studied. A summary is 
presented in Table 3.1. 
 
 INTRA-FRACTIONAL MOTION 
Intra-fraction prostate motion studied using pre- and post-treatment imaging is reported by e.g. 
Gladwish et al. (2014) and Quon et al. (2012). These studies investigate hypofractionated VMAT 
treatments of prostate cancer with fractionation schedules of 40 Gy in 5 fractions and 35 Gy in  
5 fractions, respectively. The mean 3D displacement of the prostate during treatment sessions of 
195±59 seconds is reported as 2.32±1.55 mm by Gladwish et al. (2014). They report 3D prostate 
displacements larger than 5 mm in 4% of the fractions. In the study by Quan et al. (2012), the prostate 
had a 3D displacement larger than 5 mm in 14% of the fractions. The part of the total treatment where 
the individual patient exhibited large prostate displacement was between 0-80% of the fractions. Due 
to the inter-patient variations they suggest that patients with large prostate motion are identified and 
given an individualised treatment with increased margins or other interventions. Both studies do 
conclude that prostate motion stays small in general. A limitation to studies based on only pre- and 
post-treatment images, is that any temporal prostate displacements are undetectable. 
 
Many studies have used real-time monitoring with different techniques to study the intra-fractional 
prostate motion. In this way, temporal displacements are not omitted and the actual motion pattern of 
the prostate may be mapped.  
 
In a study by Ng et al. (2012) ten patients were monitored in a total of 268 fractions using kilovoltage 
intrafraction monitoring (KIM) providing a 3D position of the prostate. They report six different types 
of prostate trajectories; stable target position, continuous drift, transient excursion, persistent 
excursion, high-frequency excursions and erratic behaviour (Figure 4). One patient exhibited 3D 
prostate displacement larger than 15 mm, where the persistent excursion (Figure 4 D) is an indication 
of a large uncorrected geometric miss (Ng et al., 2012). In general the observed motion was small, 
where 3D displacement larger than 3 mm was observed in only 4.7% of the cases. Kupelian et al. 
(2007) report similar motion patterns using the Calypso 4D localization system (Varian). In their 
study, a much higher incidence rate of prostate displacements were observed. Displacements > 3 mm 
for at least 30 cumulative seconds were reported in 41% of the fractions.  
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Figure 4. Trajectories of prostate motion during IMAT (2 arcs) reported by Ng et al (2012). The results are 
presented as control offset from initial position (mm) as a function of time (s). The motion was recorded using 
kilovoltage intrafraction monitoring (KIM) on implanted fiducial markers. Six different types of trajectories 
were identified; (A) stable target position, (B) continuous drift, (C) transient excursion, (D) persistent excursion, 
(E) high-frequency excursion and (F) erratic behaviour. The 3D (black), SI (blue), AP (green) and  
LR (red) trajectories are displayed. The grey intervals indicate beam-on. 
 
Tong et al. (2015) monitored 200 patients, treated with intact prostates during a total of 7738 fractions, 
with the Calypso 4D localization system. The VMAT treatments were generally completed in five 
minutes and the majority of the patients did not exhibit any significant prostate motion during the 
course of a single fraction. However, in 59 fractions substantial prostate drifts larger than 5 mm were 
observed within the first minute after treatment setup. A drift larger than 3 mm was observed in  
269 fractions. No typical patterns between these patients were identifiable, rather the drifts occurred 
randomly among the patients. Therefore, Tong et al suggest observations with real-time tracking 
systems of the patients for the first one or two weeks to identify the patients exhibiting severe intra-
fractional motions.  
 
Overall, prostate motion is generally small. The observed motions indicate little movement in the 
lateral direction (left-right, LR) (Ng et al., 2012, Both et al., 2011, Langen et al., 2008, Willoughby et 
al., 2006, Nederveen et al., 2002). Rather, the prostate is displaced in the anterior-posterior (AP) and 
superior-inferior (SI) directions. A study by Langen et al. (2008) also found that the AP-SI movement 
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was simultaneous, which was described as a likely consequence of bowel movements and muscular 
movement in the pelvic or lower extremities. Lin et al. (2013) observed a high correlation in AP-SI 
directional motions. They displayed the spatial distribution of the prostate motion, showing an 
elongated shape in oblique direction (AP-SI). Figure 5 is an example of the spatial distribution of the 
transponder displacement for three individual patients, including all fractions.  
 
 
Figure 5. Extract of intra-fraction prostate motion monitored using Calypso 4D in a study by Lin et al (2013). 
The plots are examples of the spatial distribution of the implanted transponder displacement in three different 
patients, including all fractions. The motion is mainly in the AP and SI directions and is found to have a non-
Gaussian distribution in most of the cases. 
 
Even though the pattern of the prostate motion is complex and unpredictable, it seems that the 
displacement of the prostate increases with time. Ballhausen et al. (2015) monitored six patients over 
84 fractions and a total of 9 hours and 25 minutes using 4D perineal ultrasound. In their article, they 
present the prostate motion as a random walk. They found that the position of the prostate relative to 
the isocenter continuously drifts over time during a fraction (Figure 6). Thus, treatment time should be 
kept as short as possible to minimise the drift. Several other studies have also found the prostate 
position to drift over time (Lovelock et al., 2015, Both et al., 2011, Langen et al., 2008). In fact, most 
available studies agree on the importance of keeping treatment times to a minimum (Tong et al., 2015, 
Lovelock et al., 2015, Ng et al., 2012, Shimizu et al., 2011, Shelton et al., 2011, Kupelian et al., 2007, 
Langen et al., 2008). 
 
 
Figure 6. The variance in prostate position for one patient (22 fractions), showing good agreement with the 
linearly increasing variance predicted by the random walk model (Ballhausen et al., 2015).  
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Table 3.1. Overview of the publications included in this literature study of prostate motion. 
Authours Year Patients 
(fractions) 
Implants Imaging modality Imaging 
frequency 
Tong, X et al 2015 236 (8660) 3 beacons Calypso 4D localization system 10 Hz 
Lovelock DM et al 2015 89 3 beacons Calypso 4D localization system 10 Hz 
Ballhausen H, et al 2015 6 (84) - 4D ultrasound (Elekta Clarity system) 2 Hz 
Huang CY et al 2015 10 (267) 
3 gold fiducial 
markers 
kV intra-fraction monitoring 5-10 Hz 
Gladwish A et al 2014 30 (150) 
3 gold fiducial 
markers 
Pre- and post-treatment orthogonal 
images 
160-388 s 
Lin Y et al 2013 31 (1024) 3 beacons Calypso 4D localization system 10 Hz 
Cramer et al 2013 143 (4137) 
Electromagnetic 
transponders 
CBCT, electromagnetic transponder 
localization 
10 Hz 
Quon, H et al 2012 53 (265) 
3 gold fiducial 
markers 
Pre- and post-treatment orthogonal 
images 
3-30 min 
Ng, JA et al 2012 10 (268) 3 fiducial markers kV intra-fraction monitoring 5-10 Hz 
Mutanga TF et al 2011 21 4 gold markers kV/MV orthogonal imaging Simulation 
Shelton J et al 2011 37 (1332) 3 beacons Calypso 4D localization system 10 Hz 
Shimizu S et al 2011 20 (4541) 3 fiducial markers Fluoroscopy, real-time tracking 1-3 min 
Poulsen PR et al 2009 17 (548) 
Electromagnetic 
transponders 
kV imaging (single)  
0.5, 1, 2  
and 5 Hz 
Langen KM et al 2008 17 (550) 3 beacons Calypso 4D localization system 10 Hz 
Kupelian PA et al 2007 41 3 beacons Calypso 4D localization system 10 Hz 
Willoughby TR et al 2006 11 3 beacons Calypso 4D localization system 10 Hz 
Mah D et al 2002 42 - Cine MRI 7-9 s 
Nederveen et al  2002 10 (251) 3 gold markers Si-flat panel imager 400 ms 
Padhani AR et al 1999 55 - Cine MRI 10 s 
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4 MATERIAL AND METHODS 
4.1 TREATMENT PLANNING 
 PATIENT MATERIAL 
The selection of the patient material was made from the database of the HYPO-RT-PC trial (Widmark 
et al., 2014). For the purpose of this study, nine patients, were chosen based on prostate size (“small”, 
“medium” and “large”) in order to investigate the treatment delivery for a range of clinical target 
volumes (CTV). The sizes were categorised based on the entire patient population (805 patients) 
registered so far in the HYPO-RT-PC study. The median CTV volume was 54 cm3, with a lower 
quartile of 44 cm3 and an upper quartile of 69 cm3. The three patients who most recently received their 
treatment were selected from each group. They had all received VMAT in Lund between 2013-2015. 
Five patients were originally treated in the conventional arm (C), 78.0 Gy in 39 fractions, while four 
patients had been treated in the hypofractionated arm (H), 42.7 Gy in 7 fractions. Patient details are 
summarized in Table 4.1. 
 
This study was approved by the Regional Ethics Board of Lund, Sweden (EPN Lund, Dnr 2013/742). 
 
Table 4.1 Patient baseline characteristics. 
Patient Age [yrs] Arm* Prostate size CTVvol [cm3] T-stage PSA [µg/l] Gleason score GLS1 + GLS2 
1 72 C Small 35.1 2 3.3 7 4 + 3 
2 61 H Small 38.6 1c 4.0 7 3 + 4 
3 73 C Small 37.2 2 4.3 7 3 + 4 
4 66 C Medium 54.1 2 4.3 7 4 + 3 
5 72 H Medium 55.0 1c 4.9 7 4 + 3 
6 71 H Medium 52.0 1c 5.1 7 3 + 4 
7 65 C Large 82.5 1c 11.0 7 3 + 4 
8 73 C Large 79.9 2 9.4 7 3 + 4 
9 70 H Large 81.6 2 6.4 7 3 + 4 
* Original treatment arm: Conventional arm (C), hypofractionated arm (H) 
 
 TREATMENT PLANS AND OPTIMIZATION  
The original delineation of the clinical target volume (CTV), planning target volume (PTV) and the 
organs at risk (OAR) were kept. Eight patients had images from CT fused with MR images. One 
patient had CT images only. The outlining of the targets and OARs was done according to the trial 
protocol (Widmark et al., 2014). The CTV was defined as the prostate on the CT image set with MR 
guidance if available. The PTV accounts for uncertainties in delineation as well as internal movements 
and set-up. The PTV is defined as the CTV plus a 7 mm isotropic margin.  
 
Three-dimensional treatment planning was done on the CT image set (3 mm slice thickness) using the 
Eclipse Treatment Planning System (TPS) version 13 (Varian Medical Systems). Absorbed dose 
calculations were performed on calculation grids of 2.5 mm, using the Analytical Anisotropic 
Algorithm (AAA) version 10.0.28. The beam qualities and the notation used when generating the 
VMAT plans were 10 MV flattened beam (10X), 6 MV unflattened beam (6FFF) and 10 MV 
unflattened beam (10FFF). The three plans were created for the conventional arm (C) and the 
hypofractionated arm (H) of the study, respectively. The same plan could not be used for both arms, as 
the optimization process was based on dose specific study protocols. In total, 54 treatment plans were 
generated (6 treatment plans for each patient).  
 
At the radiotherapy department in Lund a beam quality of 10 MV with flattening filter is used for 
prostate cancer treatments. An example of the dose distribution in a hypofractionated standard beam 
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quality plan, H10X, is presented in Figure 7. All 10X plans were created according to the normal 
clinical routines at the department. As there is not yet a clinical routine for unflattened beams treating 
prostate cancer, these were created in a similar way to give equal or improved dose distribution, while 
fulfilling the defined dose constraints. One 360° arc was used to fulfil the dose constraints in each 
plan. The collimator angle was set to 5°. The maximum available dose rate was allowed for all beams; 
600 MU/min for 10 MV flattened beams, 1400 MU/min for 6 MV unflattened beams and  
2400 MU/min for 10 MV unflattened beams. Common plan properties are reported in Table 4.2.  
 
 
Figure 7. Example of the dose distribution, showing the isodose levels of 30% (light blue), 90% (green)  
and 100% (yellow) in the hypofractionated 10 MV flattened (H10X) treatment plan for patient 1. 
 
Table 4.2. Common properties of the VMAT treatment plans created for each patient.  
 
The dose constraints are specified in the HYPO-RT-PC study protocol version 6 and are reported in 
Table 4.3. The initial setting used for the VMAT optimization was start dose, end dose and fall-off for 
Normal Tissue Objectives (NTO) and upper and lower objectives on the PTV. When necessary, a 
lower objective of the prescribed dose was also introduced on the CTV. Upper objectives on the 
rectum were lowered interactively during optimization. Fixed upper objectives were used on the right 
and left femoral heads. The priorities on the OARs were all lower than for the NTO, the PTV and the 
CTV. Two optimizations were performed on every treatment plan. All plans were normalized to the 
PTV average dose in accordance with the trial protocol. 
 
The objectives were optimized individually for each plan in order to fulfil the dose constraints as 
defined in the protocol. Other studies (Zwahlen et al., 2012, Gasic et al., 2014) report on using the 
same objectives on all plans for each patient. However, this would not suit the aim of this particular 
study since the purpose is to investigate the clinical relevance of the different beam qualities and not 
an evaluation of the treatment planning system itself.  
Plan 
 
Study arm 
 
Prescribed  
dose 
Energy 
 
Flattening  
filter 
Collimator  
angle [°] 
Arc 
 
Max doserate  
[MU/min] 
C10X Conventional 2.0 Gy x 39 10 MV Yes 5 1 600 
H10X Hypo 6.1 Gy x 7 10 MV Yes 5 1 600 
C6FFF Conventional 2.0 Gy x 39 6 MV No 5 1 1400 
H6FFF Hypo 6.1 Gy x 7 6 MV No 5 1 1400 
C10FFF Conventional 2.0 Gy x 39 10 MV No 5 1 2400 
H10FFF Hypo 6.1 Gy x 7 10 MV No 5 1 2400 
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The treatment plans were visually reviewed and approved by a senior clinical physician at the 
radiotherapy department.  
 
Table 4.3. Dose-volume objectives to target volumes and organs at risk. 
     
Priority Volume Conventional arm Hypofractionated arm Comment 
     
1 CTV Dmin ≥ 95% 
Dmin ≥ 74 Gy 
Dmin ≥ 95% 
Dmin  ≥ 40.6 Gy 
The minimum dose to CTV shall 
be greater than or equal to 95% of 
the prescribed dose, i.e. Dmean,PTV 
2 PTV V74Gy ≥ 95% 
V95% ≥ 95% 
V40.6Gy ≥ 95% 
V95% ≥ 95% 
The 95% isodose shall cover at 
least 95% of PTV. 
3 Rectum V70Gy ≤ 15% 
V90% ≤ 15% 
V38.4Gy ≤ 15% 
V90% ≤ 15% 
Less than 15% of the outlined 
rectal volume should receive doses 
greater than 90% of the prescribed 
dose. 
4 PTV D99% ≥ 70 Gy  
D99% ≥ 90% 
D99% ≥ 38.4 Gy 
D99% ≥ 90% 
The “near minimum dose” to PTV 
should be greater than or equal to 
90% of the prescribed dose. 
5 Rectum V59Gy ≤ 35% 
V75% ≤ 35% 
V32Gy ≤ 35% 
V75% ≤ 35% 
Less than 35% of the outlined 
rectal volume should receive doses 
greater than 75% of the prescribed 
dose. 
6 Femoral 
heads 
Dmax≤ 55 Gy 
Dmax ≤ 70% 
Dmax≤ 29.9 Gy 
Dmax≤ 70% 
The maximum dose to the femoral 
heads should be less than or equal 
to 70% of the prescribed dose. 
7 Rectum V51Gy ≤ 45% 
V65%  ≤ 45% 
V28Gy ≤ 45% 
V65% ≤ 45% 
Less than 45% of the outlined 
rectal volume should receive doses 
greater than 65% of the prescribed 
dose. 
8 Body Dmax ≤ 82 Gy 
Dmax ≤ 105% 
Dmax ≤ 44.9 Gy 
Dmax ≤ 105% 
The maximum global dose should 
be less than or equal to 105% of 
the prescribed dose. 
 
The DVH parameters stated in the trial protocol (Table 4.3) were extracted from Eclipse. The mean 
and the standard deviation for the nine patients for each of the beam qualities and treatment arms were 
calculated. Combined DVHs were created (displaying PTV, CTV and rectum) using the mean of all 
patients for each plan category. 
 
 
4.1.2.1 RECTUM PARAMETERS 
In the treatment protocol it is stated that the anterior-posterior (AP) diameter of rectum should not 
exceed 40 mm at the level of the prostate position in the CT image set. However, the patients do not 
receive any guidelines on emptying rectum prior to the CT scan or the treatment sessions. The only 
recommendation is that the patient should have a “comfortably filled bladder” (Widmark et al., 2014).  
 
The maximum AP rectum diameter in the cohort of patients selected for this study was measured in 
each of the CT image sets. The volumetric overlap in the structures of rectum and PTV was also 
calculated, using a Boolean operator in Eclipse.   
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 VERIFICATION TREATMENT PLANS 
The treatment plans were recalculated, creating verification plans where the patient’s CT data set was 
replaced by the Delta4 phantom (Figure 8). The verification plan was imported to the Delta4 software, 
allowing for a comparison between the measured and the calculated doses. This patient QA was 
performed for all VMAT patients.  
 
 
 
Figure 8. An example of the dose distribution in the verification plan of conventional flattened 10 MV (C10X) 
for one of the patients. The dose distribution is displayed in the transversal (upper left), coronal (lower left) and 
sagittal (lower right) planes. The upper right image shows the starting position of the MLC in beams eye view. 
 
4.2 TREATMENT DELIVERY 
The medical linac used for measurements in this study 
was a Varian TrueBeam™. The output of the linac was 
checked by performing the department’s monthly dose 
output verification procedure before the measurements 
were run. The tolerance on dose deviations for these 
tests is set to 1%. The low tolerance ensures that large 
drifts in dose output are prevented. Gantry and 
collimator angles were set to 0°. The ion chamber 
(PTW 30012) was placed inside a polystyrene block 
attached to the gantry. Temperature and pressure were 
measured. A field size of 15x15 cm2 was set using the 
collimator jaws; the multi leaf collimator (MLC) was 
completely withdrawn. The ion chamber was pre-irradiated with 500 MU. Three measurements of  
100 MU for each of the beam qualities 10 MV, 6 MV FFF and 10 MV FFF were recorded. The 
reading of the electrometer was corrected for pressure and temperature and compared to a reference 
value. For all beam qualities, dose deviations were approximately 0.5%, which is below the tolerance 
for monthly controls. Basic output and dose profile controls are performed on a daily basis using a 2D 
quality assurance device. 
 
To ensure the quality of the dose measurements, the Delta4 dosimetry system is calibrated at 
installation and thereafter as appropriate. Before the treatment plans of this study were measured a full 
calibration was carried out. The phantom was irradiated using a 10x10 cm2 open field for all beam 
qualities. A cross-calibration was performed for the two Delta4 detector planes. A relative calibration 
 
        Figure 9. The Delta4 phantom setup. 
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was performed for one photon energy (with flattening filter) in order to determine the sensitivity of 
every individual detector. For the absolute calibration all available photon energies were evaluated, 
both flattened and unflattened beams. Finally a directional calibration was made to determine 
variations due to rotational direction-dependence. The detector planes were irradiated upside down 
and the measurements were compared to the ones with normal beam incidence to identify any 
deviations. 
 
After the calibration, the Delta4 phantom was carefully positioned isocentrically using the set-up lasers  
(Figure 9). The phantom was connected to the accelerator, sending a trigger pulse to the phantom to 
start the measurement collection. Each of the patient specific treatment plans were delivered to the 
phantom, whereby the collected data was organized based on gantry angle. The planned dose 
distribution was imported from the TPS. In this work the planned dose for each control point was 
compared to the corresponding measured dose by the diodes of the two orthogonal detector planes 
using gamma evaluation.  
 
Treatment times were recorded manually on a stopwatch and in the verification system (Aria). 
 
 
4.3 MOTION STUDY 
A study on the effects of prostatic displacement during treatment delivery was also designed. For this 
purpose the patient with the longest treatment times was selected. The treatment plans H10X and 
H10FFF were used to evaluate the impact of intrafractional prostate motion. To simulate motion the 
Delta4 was connected to the Hexamotion module (ScandiDos, Uppsala, Sweden). Trajectory data were 
received from Ng et al. (2012), University of Sydney, Australia. The patterns are shown in Figure 4. 
 
A trajectory convertor was constructed in MATLAB to adapt the data to the format used as input files 
to the Hexamotion. The time resolution and movements that were too rapid or had too steep gradients 
to be accepted by the Hexamotion were slightly adjusted, keeping the characteristics of the trajectory.  
 
The selected treatment plans were delivered for six different motion patterns (stable trajectory, 
continuous drift, persistent excursion, transient excursion, high-frequency excursions and erratic 
behaviour). The plans were also delivered in a static reference situation with the Delta4 positioned in 
the defined origin. The treatment delivery (beam-on) was started at the same time as the trajectory 
(Hexamotion), for all but two trajectories. These two were cropped in order to be able to study the 
effects. Delivery with transient excursion was started 60 s into the motion pattern for both plans. This 
time interval may represent the time it takes to review the daily set-up images, before the treatment. 
The delivery with transient excursion was started at 175 s for H10X and at 200 s for H10FFF to 
include the peak in the trajectory and investigate the effect of the temporal displacement. 
 
All results were evaluated relative to the static delivery.  
 
 
4.4 EVALUATION OF MEASUREMENTS 
 PLAN EVALUATION 
The delivered dose distribution of the treatment plans was measured with the Delta4 pre-treatment 
verification phantom. The results obtained in the ScandiDos software are based on dose deviation, 
distance-to-agreement and gamma indices (section 3.6). Histograms from the three evaluation methods 
are presented in the software evaluation dialog as well as dose profiles showing the calculated and the 
measured doses.  
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The homogeneity index (HI) and the conformity index (CI) were calculated and used as a further 
comparison of the plan quality. Variables included in the calculation were extracted from the 
respective DVH. The homogeneity index was calculated, as defined in ICRU 83, from the following 
expression  
PQ = %ST%UV%                    (13) 
 
where D2% is the near-maximum absorbed dose, D98% is the near-minimum dose and D50% is the 
median dose. 
 
The conformity index, as defined by Paddick (2000), was calculated from 
 
WQ = XYZ[\XY∙]^Y                 (14) 
 
where TV is the target volume (PTV), PIV is the volume within the prescribed isodose (V95% for the 
structure BODY) and TVPIV is the volume of the PTV surrounded by the prescribed isodose (V95% for 
the PTV). 
 
The evaluation of the treatment delivery was done using gamma indices with different passing criteria 
(3% and 2mm, 2% and 2mm, 2% and 1mm and 1% and 1mm, respectively). The calculated dose 
distribution is compared to the measured dose, collected by each diode of the two orthogonal detector 
planes. In the department in Lund a pass rate of 90 % is required for the gamma criteria 3% and 2 mm 
for all clinical treatment plans. However, if the pass rate is below 95 % the plan is further analysed to 
evaluate the clinical relevance of any deviations. Additionally, the dose distribution profile to profile 
and point to point is also reviewed for the individual treatment plans. 
 
 
 STATISTICAL ANALYSIS 
Before any statistical tests were run, the results were checked for normality using the Kolmogorov-
Smirnov test.  
 
A two-tailed paired sampled student’s t-test was used to evaluate if any differences between the 
flattened and unflattened beams were significant. The level of significance was set to 5 %. Correlation 
between the different parameters was investigated using Pearson’s correlation coefficient and linear 
regression.   
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5 RESULTS 
 
The results presented below are based on six subgroups of treatment plans, using beam qualities of 
10 MV, 6 MV FFF and 10 MV FFF for both conventional and hypofractionation schedules, created 
for nine different patients (54 treatment plans in total). 
 
5.1 TREATMENT PLAN QUALITY: DOSE DISTRIBUTION 
The fundamental parameters of interest in this study were beam quality and treatment technique. 
Hence, all treatment plans were evaluated on dose-volume constraints (based on the protocol described 
in Table 4.3), homogeneity and conformity index, plan complexity (expressed as MU/Gy) and visual 
appearance of the homogeneity/inhomogeneity in dose distribution.  
 
The treatment plans were reviewed by a senior physician in the radiotherapy department, who 
approved all plans to be clinically acceptable. The dose coverage of the target was met in all beam 
qualities. A thorough analysis of the plans was carried out on each of the cumulative dose-volume 
histograms (DVH). The dose constraints, specified in the HYPO-RT-PC protocol (Table 4.3), were 
compared to the corresponding value derived from the DVH. The average cumulative DVH for all 
patiens, computed for the six subgroups, are presented in Figure 10. The main prioritised structures are 
included in the DVH; CTV, PTV and rectum.  
 
All objectives were met by all patients. Comparing the mean of all nine patients, no significant 
differences were found between the different beam qualities or between the different fractionation 
schedules. A detailed summary of the mean values from all patiens (with one standard deviation 
uncertainty) for all protocol parameters can be found in Table 5.1. 
 
The dose bath was calculated for all beam qualities, using V10% and V5% for the total CT volume. No 
significant differences were found for the mean of the nine patients between flattened and unflattened 
beams. The volumes were slightly smaller, but not significant, for 10FFF than for both 10X and 6FFF 
in the conventional and hypofractionated plans. These results were based on the calculations from the 
treatment planning system. Further measurements in the low dose area would be required for a more 
accurate evaluation of the dose bath.  
 
The homogeneity and the conformity indices of the PTV were calculated using equations 13 and 14, 
respectively (Table 5.1). The results of the three beam qualities in both experimental arms were all 
within one standard deviation relative to eachother. Hence, there was no statistical significance in 
target coverage between flattened and unflattened beams.  
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Figure 10. The cumulative mean dose volume histograms (DVH) computed for all patients for each of 
the treatment plans. The red and green solid lines represent the mean cumulative dose to PTV and 
CTV, respectively. The blue solid line represents the mean cumulative dose to rectum and the blue 
dashed lines illustrate the range of mean rectum dose in the patient cohort.  
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Table 5.1 DVH parameters (mean values ±1SD), based on all patients. Upper table displays the results for the 
conventional plans and lower table displays the hypofractionated plans. 
                      
 Objective C10X   SD C10FFF   SD C6FFF   SD 
CTV Mean [Gy] 78.37 ± 0.07 78.46 ± 0.11 78.40 ± 0.09 
CTV Min ≥ 74 Gy 76.13 ± 0.67 76.08 ± 0.53 75.86 ± 0.44 
PTV V95% ≥ 95% 99.44 ± 0.35 99.09 ± 0.73 99.49 ± 0.43 
Rectum V90% ≤ 15% 11.22 ± 2.90 11.29 ± 2.94 11.79 ± 2.91 
PTV D99% ≥ 70 Gy 74.60 ± 0.44 74.22 ± 0.69 74.74 ± 0.57 
Rectum V75% ≤ 35% 18.52 ± 4.21 19.87 ± 4.70 20.01 ± 4.73 
FH dx Max ≤ 55 Gy 30.59 ± 5.22 30.26 ± 3.44 30.20 ± 6.41 
FH sin Max ≤ 55 Gy 33.47 ± 5.39 31.87 ± 4.40 31.85 ± 5.11 
Rectum V65% ≤ 45% 24.52 ± 5.32 27.31 ± 6.40 27.61 ± 7.01 
Body Max ≤ 82 Gy 81.01 ± 0.34 81.40 ± 0.50 81.64 ± 0.86 
Body Mean [Gy] 3.85 ± 0.58 3.75 ± 0.51 4.13 ± 0.59 
Body V10% [%] 14.40 ± 1.99 13.89 ± 1.79 14.47 ± 1.98 
Body V5% [%] 17.57 ± 2.10 17.10 ± 1.91 17.69 ± 1.99 
CI 1 0.889 ± 0.016 0.894 ± 0.015 0.871 ± 0.021 
HI 0 0.054 ± 0.006 0.061 ± 0.009 0.053 ± 0.007 
                      
 Objective H10X   SD H10FFF   SD H6FFF   SD 
CTV Mean [Gy] 42.90 ± 0.04 42.94 ± 0.06 42.94 ± 0.05 
CTV Min ≥ 40.6 Gy 41.82 ± 0.24 41.55 ± 0.40 41.54 ± 0.26 
PTV V95% ≥ 95% 99.43 ± 0.43 99.26 ± 0.49 99.46 ± 0.59 
Rectum V90% ≤ 15% 11.31 ± 2.71 11.21 ± 2.91 11.28 ± 2.80 
PTV D99% ≥ 38.4 Gy 40.83 ± 0.28 40.73 ± 0.28 40.88 ± 0.37 
Rectum V75% ≤ 35% 18.98 ± 3.80 19.11 ± 3.80 18.65 ± 4.26 
FH dx Max ≤ 29.9 Gy 16.96 ± 3.91 17.36 ± 3.06 16.81 ± 3.48 
FH sin Max ≤ 29.9 Gy 17.53 ± 2.71 17.54 ± 3.24 17.82 ± 2.58 
Rectum V65% ≤ 45% 25.25 ± 4.64 26.21 ± 5.41 24.98 ± 5.77 
Body Max ≤ 45.7 Gy 44.38 ± 0.27 44.61 ± 0.32 44.74 ± 0.51 
Body Mean [Gy] 2.08 ± 0.31 2.07 ± 0.30 2.27 ± 0.32 
Body V10% [%] 14.27 ± 2.00 14.07 ± 1.97 14.65 ± 1.93 
Body V5% [%] 17.49 ± 2.06 17.13 ± 2.02 17.77 ± 2.01 
CI 1 0.891 ± 0.013 0.891 ± 0.013 0.877 ± 0.017 
HI 0 0.055 ± 0.007 0.059 ± 0.007 0.055 ± 0.010 
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The number of monitor units (MU) per dose unit (Gy), here defining the complexity of the treatment 
plans, are presented in the boxplot in Figure 11. Out of all the data, two values were considered 
outliers (deviated more than ±2.7σ), one value in the group C10X and one in H6FFF, plotted 
individually as red crosses. All sets of data were found to be normally distributed. An ANOVA test 
was performed on the variance between the six groups. The variance between the groups was found to 
be larger than that within the groups. The p-value, p=4e-08, implies that there is a significant 
difference in complexity of the plans between the groups.  
 
The differences between the groups of beam qualities and fractionation schedules were statistically 
evaluated using a two-tailed paired sample student’s t-test. The number of MU/Gy was significantly 
larger for all FFF plans (p<0.05) except for the conventional 10FFF plans (p=0.19). No significant 
difference was found comparing each of the beam qualities pairwise between the conventional and the 
hypofractionated plans. The 6FFF plans required the largest number of MU/Gy (p<0.05).  
 
  
Figure 11. The complexity of the treatment plans for all patients, expressed in monitor units (MU) per 
prescribed dose (Gy). The line inside each box indicates the median, the box itself represents the 25th and 75th 
percentiles and the error bars are the range of values, excluding outliers. The outliers in the data are shown as red 
crosses (values deviating more than ±2.7σ). 
 
A new anatomical structure was introduced, defined as the overlapping volume of rectum and PTV. 
For all patients, the volume of this structure was calculated. The defined volume is one of the 
conflicting areas in the dose optimization; the lower dose constraints on the PTV versus the upper 
dose constraints on rectum. The complexity (MU/Gy) was thus plotted as a function of the size of the 
overlapping volume. The results are presented in Figure 12. Moderate positive correlations  
(R2 = 0.44 to 0.82) are observed for all groups of beam qualities, i.e. a larger overlapping volume 
requires a more complex plan in order to fulfil the dose constraints.  
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Figure 12. Complexity for the conventional (left) and the hypofractionated (right) treatment plans plotted as a 
function of volume overlap between rectum and PTV. A linear fit is applied to each of the subgroups of different 
beam qualities. 
 
5.2 TREATMENT PLAN QUALITY: DELIVERY 
 TREATMENT TIME 
The beam-on time for each plan delivery was measured. The results are presented in Figure 13. In the 
original treatment plans from the HYPO-RT-PC study (5 conventional, 4 hypo), the mean treatment 
times were 1.0 minute for C10X and 2.1 minutes for H10X. These are close to the times measured in 
this study. The conventional treatment plans were all delivered in 1.0 minute, with the exception of 
one C10X plan delivered in 1.1 minutes. The H10X plans had a mean delivery of 2.3 minutes  
(range: 2.1-2.8 minutes). For the unflattened beams the treatment times were significantly shorter; 
H6FFF plans were delivered in 1.3 minutes (range: 1.2-1.6 minutes) and the H10FFF plans were 
delivered in 1.0 minute (range: 1.00-1.04 minutes).  
 
  
Figure 13. Beam-on time delivering single-arc treatments for all plans and beam qualities. Error bars indicate 
the range of recorded treatment times based on all patients in each subgroup of plans. The line inside each box is 
the mean treatment time. The outliers of the data are shown as red crosses (values deviating more than ±2.7σ). 
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If the treatment time is simulated without 
accounting for the limited speed of the gantry, a 
further reduction in delivery time is observed for 
H10FFF (Figure 14). The 6.1 Gy per fraction 
could theoretically be delivered in less than one 
minute.   
  
 TREATMENT DELIVERY 
The quality of treatment delivery for each of the 
created treatment plans was evaluated using 
measurements from the Delta4 dosimetry 
phantom. The results were evaluated in the 
ScandiDos software using gamma indices with 
different criteria (from 3%, 2 mm to 1%, 1 mm). 
The pass rates for the treatment plans, divided 
into subgroup based on prostate size (“small”, 
“medium” and “large”) are presented as a 
function of complexity.  
 
The results of the plans evaluated with the clinical acceptance gamma criteria used at the department 
in Lund (3%, 2 mm) are presented in Figure 15. The results of the pass rate for the 2%, 2 mm, the 2%, 
1 mm and the 1%, 1 mm are presented in Figure 16, Figure 17 and Figure 18, respectively.  
 
The subplots of Figure 15-18 each contain nine data points; the three patients with the defined prostate 
size (“small”, “medium” or “large”) and for every patient, the three corresponding treatment plans 
(conventional (left) or hypo (right)). The pass rate observed for the gamma criteria 3%, 2 mm  
(Figure 15) was well above the critical value of 90%, the lowest pass rate being 98.8%. Most plans 
had 100% of the points passing. No correlation was found between pass rate and prostate size or 
between pass rate and complexity. Furthermore, there was no significant difference in pass rate 
between the different beam qualities.  
 
The pass rate decreased with increasing the stringencies of the gamma criteria. Similarly to the results 
of the 3%, 2 mm pass rate, no correlations were found between pass rate and prostate size, complexity 
or beam quality. All plans appeared to be delivered equally well.   
 
 
 
Pass rate (3%, 2 mm) 
Conventional    Hypo 
  
Figure 15. Results of measurements for all nine patients and all six treatment plans using  
gamma criteria 3 %, 2 mm. The reference value is the calculated dose. 
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Figure 14. Theoretical treatment times of the hypo-
fractionated plans, calculated from the number of 
MU per dose rate. The dashed line represents the 
actual minimum treatment time (1 min) due to 
restrictions on gantry rotation. 
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Pass rate (2%, 2 mm) 
Conventional    Hypo 
  
Figure 16. Results of measurements for all nine patients and all six treatment plans using  
gamma criteria 2 %, 2 mm. The reference value is the calculated dose. 
 
Pass rate (2%, 1 mm) 
Conventional    Hypo 
  
Figure 17. Results of measurements for all nine patients and all six treatment plans using  
gamma criteria 2 %, 1 mm. The reference value is the calculated dose. 
 
Pass rate (1%, 1 mm) 
Conventional    Hypo 
   
Figure 18. Results of measurements for all nine patients and all six treatment plans using  
gamma criteria 1 %, 1 mm. The reference value is the calculated dose. 
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5.3 MOTION STUDY 
A motion study on the impact of prostate displacement was carried out using six different motion 
trajectories. The trajectory data was recorded by Ng et al (2012) and represent six typically observed 
prostate motion patterns. Each trajectory below was simulated for one patient during one fraction. The 
results were evaluated with a static treatment delivery as reference for the plans H10X and H10FFF. 
Below are the results from the evaluation of the mean dose using the same gamma criteria as above. 
Each trajectory is presented together with it’s corresponding results. Note that the range of the y-axis, 
showing the prostatic displacement, varies between different trajectories.  
 
The prostatic displacement of the ”stable trajectory” (ST), Figure 19, and the “continuous drift” (CD), 
Figure 20, does not exceed more than 1 mm displacement in any direciton within the time frame of the 
two plan deliveries. The pass rate fraction relative the static delivery is 100% for all gamma criteria 
investigated, except for the H10X plan at 1% 1mm, which is just below. The treatements with the ST 
and the CD are delivered equally well, despite small offsets in position, for both the flattened and the 
unflattened beam.  
 
The trajectory of ”persistent excursion” (PE), Figure 21, was run for 60 s before the treatment was 
initiated. The effects on the pass rate of the H10X, delivered in 2.5 minutes, are more severe than on 
the H10FFF, delivered in 1.0 minute. Only for gamma criterion 1% 1mm is the pass rate for H10FFF 
less than for the static delivery. 
 
The effect due the “transient excursion” (TE), Figure 22, was investigated by initiating the treatment 
such that it included the peak in offset in the respective time frame. The H10X plan was started 175 s 
into the trajectory, while the H10FFF plan was started after 200 s. The decrease in number of points 
passing the gamma criterion increases with stricter criteria for both treatment plans. The reduction in 
pass rate is somewhat greater for the H10FFF plan than for the H10X. 
 
The effect observed in the results for the “high-frequency excursions” (HE), Figure 23, is similar to 
what is also observed for the “erratic behaviour” (EB), Figure 24. The pass rate decreases with 
stringency in gamma criteria for both treatment plans compared to the static delivery, where the largest 
decrease is observed for the H10X. When the gamma criterion is set to 1% 1mm, half as many points 
pass for the HE and the EB compared to the static case.   
 
 
  
Figure 19. The stable trajectory (ST) is presented in three dimensions (left). The dashed and the solid black lines 
represent the end of the H10FFF treatment and the H10X treatment, respectively. The corresponding results of 
the gamma evaluation (right) relative to a static delivery are presented for H10FFF (grey) and H10X (black). 
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Figure 20. The trajectory of continuous drift (CD) is presented in three dimensions (left). The dashed and the 
solid black lines represent the end of the H10FFF treatment and the H10X treatment, respectively. The 
corresponding results of the gamma evaluation (right) relative to a static delivery are presented for H10FFF 
(grey) and H10X (black). 
 
Figure 21. The trajectory of persistent excursion (PE) is presented in three dimensions (left). The dashed and the 
solid black lines represent the end of the H10FFF treatment and the H10X treatment, respectively. The 
corresponding results of the gamma evaluation (right) relative to a static delivery are presented for H10FFF 
(grey) and H10X (black). The treatment delivery was started at time = 60 s. 
 
Figure 22. The trajectory of transient excursion (TE) is presented in three dimensions (left). The dashed and the 
solid black lines represent the end of the H10FFF treatment and the H10X treatment, respectively. The 
corresponding results of the gamma evaluation (right) relative to a static delivery are presented for H10FFF 
(grey) and H10X (black). The treatment delivery was started at time = 175 s for H10X and at time = 200 s for 
H10FFF. 
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Figure 23. The trajectory of high-frequency excursions (HE) is presented in three dimensions (left). The dashed 
and the solid black lines represent the end of the H10FFF treatment and the H10X treatment, respectively. The 
corresponding results of the gamma evaluation (right) relative to a static delivery are presented for H10FFF 
(grey) and H10X (black). 
 
Figure 24. The trajectory of erratic behaviour (EB) is presented in three dimensions (left). The dashed and the 
solid black lines represent the end of the H10FFF treatment and the H10X treatment, respectively. The 
corresponding results of the gamma evaluation (right) relative to a static delivery are presented for H10FFF 
(grey) and H10X (black). 
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6 DISCUSSION 
6.1 TREATMENT PLAN QUALITY: DOSE DISTRIBUTION 
The results of this treatment planning study comparing plans for prostate cancer, performed using 
beams with and without flattening filter, show that the plans are generally of equal quality. None of 
the parameters extracted from the dose-volume histograms (DVH) differed significantly when 
comparing treatment plans with and without flattening filter. Part of the aim of this study was to 
investigate if the FFF plans could be generated with the same or improved quality as the standard 
plans. No improvement in treatment plan quality was observed, but the aim is nevertheless fulfilled, 
with similar dosimetric results for both flattened and unflattened beams.  
 
The patients in the study were divided into three groups based on the volume of the prostate; “small”, 
“medium” and “large”. The mean of the large PTVs was more than double the volume of the small 
PTVs. Despite the large variation in target size, no compromise in plan quality was observed between 
the beam qualities.  The plans were also robust to patient weight. For a larger patient a possible benefit 
might be expected from the FFF beams, since there is less variation in dose characteristics with depth 
for an unflattened beam. However, no such effect was observed in this cohort of patients.  
 
All dose-volume objectives for all patients and all plans were within the constraints of the  
HYPO-RT-PC study protocol. Hence, all treatment plans would be acceptable for clinical use. The 
manual work during the optimization process of the treatment plans was similar irrespective of what 
beam quality was chosen. Planning the prostate cases with FFF beams instead of standard beams 
would therefore not imply any additional workload on the dose planning staff.  
 
Although a higher integral dose to healthy tissue associated with unflattened beams has been of 
concern (Vassiliev et al., 2009), no significant difference between the beam qualities in integral dose, 
V10% or V5%, was observed in this study. The dose bath as well as the integral dose was actually lower 
for the 10 MV FFF plans than for plans of the same energy with flattening filter. The corresponding 
doses for 6 MV FFF were marginally higher, which is in agreement with dose characteristics of lower 
energies and therefore expected. Either way, none of these differences were significant (p>0.05). It is 
worth noting that these results were based on calculations from the treatment planning system, making 
them indicative rather than definite. The accuracy in dose well outside the treatment field is limited. 
Further measurement in the low dose region would be required in order to make any definitive 
conclusions about the difference in dose bath between flattened and unflattened beams. 
 
A parameter that differed significantly between the different beam qualities was the complexity 
expressed as monitor units per delivered absorbed dose, MU/Gy, (Figure 11). The results were 
presented per dose (Gy) to allow comparison also between the conventional and the hypofractionated 
plans. The FFF plans required additional MU/Gy compared to standard plans, for both treatment arms. 
However, the MU/Gy for the C10FFF was not significantly larger than for the C10X. In practice an 
increase in MU/Gy implies an increase in treatment time. This effect is compensated by the increase in 
dose rate associated with removing the flattening filter. Depending on the degree of complexity and 
the available dose rate (related to photon energy), this is likely to counteract the additional MU/Gy and 
may even end up in decreasing the treatment time. In this study the increase in complexity is only a 
few percentages between the different beam qualities, while the increase in maximum dose rate 
between 10X and 10FFF is 400 %. This suggests that the increase in complexity on this level is not of 
clinical importance, which was indeed shown in the results from the measurements using the Delta4. It 
is also in agreement with the results found by Gasic et al. (2014). 
 
The majority of the plans fulfilled the dose constraints after the first optimization. There was however 
a few patients for which it was more challenging to meet the constraints, the rectum dose in particular. 
It is rather obvious that there will be a conflict in optimization between satisfactory target coverage 
and limited rectum dose, considering the rectum position being in proximity to the prostate and in 
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some cases even in contact with it. To investigate the correlation between plan complexity and the 
properties of the rectum, a structure defined as the overlap of PTV and rectum was introduced. It was 
found that there was a moderate, positive correlation between the size of the overlapping volume and 
complexity (Figure 12), implying that a larger overlap requires a more complex treatment plan. 
Unsurprisingly, the maximum value of the rectum diameter (at the level of the prostate) was found to 
be larger for the patients with a larger overlap in structures. Furthermore, a larger rectum diameter is 
associated with rectal filling. A full rectum has been shown more likely to induce prostate 
displacement (Ghilezan et al., 2005, Padhani et al., 1999). More specifically, Padhani with colleagues 
observed that patients with a rectum AP diameter > 37 mm were more prone to intra-fractional rectal 
movement, which may cause prostate displacements. In the currently on-going HYPO-RT-PC study 
the patients are not given any recommendations prior to initial scanning or treatment. However, 
according to the protocol the patients with a rectum diameter > 40 mm should be CT re-scanned 
before treatment planning. 
 
To summarize the results of the dose distribution in the treatment plans, there is no significant 
difference in plan parameters between the different beam qualities. The treatment plans using FFF,  
10 or 6 MV photons, generate not superior, but at least equal plans as standard 10 MV beams. This 
proves that it is feasible to generate VMAT treatment plans for extreme hypofractionation of prostate 
cancer using FFF-technique.  
 
6.2 TREATMENT PLAN QUALITY: DELIVERY 
Besides proving equal plan qualities, the aim of this study was to investigate if FFF could be used to 
decrease the treatment time for the hypofractionated deliveries. The beam-on time was measured for 
each of the treatments, delivered onto the Delta4 pre-treatment verification phantom. The limitation to 
the standard beam and the 6 MV FFF lies in the dose rate. In some cases the modulation of the MLC 
might limit the gantry rotation, depending on the complexity of the segment. For the 10 MV FFF, the 
maximum available dose rate is 2400 MU/min. In this case, the gantry rotation becomes the limiting 
factor, which, due to safety regulations, is rotating at a maximum speed of one arc per minute. The 
decrease is still evident. Using 10 MV FFF, the treatment time of delivering 6.1 Gy/fraction is less 
than half the time of a standard 10 MV beam. These results are consistent with those by Zwahlen et al. 
(2012) and Gasic et al. (2014), both of which report significantly reduced treatment times with FFF. 
 
This study differs from previous work in that the optimized plans were created with individual 
objectives for each plan to ensure clinically relevant treatment plans. Because of the request on 
decreasing treatment time for the hypofractionated cases from the clinic, it has been important to 
simulate the authentic clinical process through all the steps of the evaluation. Accordingly, all plans 
were verified through pre-treatment measurements using the dosimetry phantom Delta4. Still, it was 
the final results of the evaluation that were of interest in this thesis work and not the specific 
objectives used during treatment planning. 
 
The results from the gamma-evaluation showed that all treatment plans passed the clinical tolerance 
gamma criterion 3%, 2 mm. For the more stringent gamma criteria, the pass rate was observed to 
decrease with increasing stringency. The spread in pass rate was simultaneously increasing, which is 
expected. With stricter criteria smaller effects become prominent. The first points to fail were the field 
edges, due to high dose gradients. Also, with strong modulation within the fields it was generally the 
highest gradients that failed. The pass rate was acceptable down to 2%, 1 mm, indicating excellent 
delivery of the treatment plans. Only for gamma criterion 1%, 1 mm the majority of the plans had a 
pass rate below 90%. This is unlikely to have any clinical relevance for the patient.  
 
No correlation between pass rate and prostate size (“small”, “medium” and “large”) was found. There 
seems to be no compromise in treatment delivery, despite variations in target size. Even the large 
prostate is a small enough target to be covered by the “flatter” central part of the FFF beam, making 
the profile very much alike the flattened beam. The correlation between pass rate and different 
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energies was also found to be non-significant in both treatment arms. Again, it is shown that it is 
feasible to deliver extreme hypofractionated radiotherapy for prostate cancer combining VMAT with 
FFF-technique. Other studies have shown similar results. Gasic et al. (2014) compared VMAT with 
and without flattening filter for five different types of tumours, one of them being prostate cancer. 
According to their results there was generally no significant dose difference in the treatment plans 
between the two techniques. They found the greatest benefit using FFF for small target volumes 
treated with high fractionation doses, significantly decreasing treatment times while maintaining plan 
quality. Alongi et al. (2013) gave a preliminary report of a phase II study on evaluating the safety of 
hypofractionated stereotactic body radiotherapy (SBRT) for prostate cancer using VMAT without 
flattening filter. The patients were treated with a schedule of 35 Gy in five fractions. The dosimetric 
evaluation showed that all dose-volume objectives were fulfilled for all patients. Preliminary results 
on outcome and toxicity implied that the FFF SBRT was feasible, delivering the treatment in 
approximately 2 minutes. Similarly, Ferrer Gonzalez et al. (2015) also showed that SBRT (35 Gy in 
five fractions) was feasible with VMAT FFF, but emphasised the need for longer follow up before any 
definite conclusions about late toxicity and outcome are possible. 
 
There are recent publications describing the implementation of QA systems and gamma evaluation. 
For example, Arumugam et al. (2015) recommends a 2%, 2mm global gamma criterion combined with 
a minimum 85% pass rate for clinical verification of VMAT plans. The main limitation of the gamma 
method is that it only provides information about the percentage of points which fail the target criteria, 
and not the anatomical location in of these failures. Several groups have evaluated the performance of 
various available QA systems (Fredh et al. (2013), Coleman and Skourou (2013) and Nilsson et al. 
(2013)), the common finding being that it is often difficult to identify dosimetric errors using only a 
single gamma index. Recent developments in analysis have focussed more on comparing measured 
dosimetric deviations relative to anatomy and planned dose distribution. However, the ability to 
identify the errors also seems to depend on the treatment site and plan. Fredh et al. (2013) studied four 
different QA systems, including the Delta4, evaluating four different IMRT plans with and without 
introduced errors. For the prostate case evaluated using the Delta4PT, all of the original plans had a 
pass rate >95%. Furthermore, the introduced errors of 3% dose deviation and 4 mm MLC error had the 
highest gamma failure rate. This implies that the system successfully identifies these types of errors. 
The Delta4 had the lowest failure rate for introduced collimator angle deviations of 2 and 5 degrees. 
However, in practice this is likely to have little dosimetric significance on a prostate cancer treatment.  
In this study, all of the treatment plans showed pass rates >95% using gamma criterion 3%, 2mm. The 
gamma evaluation was performed on treatment plans generated for each individual patient using 
different beam qualities, thereby excluding any inter-patient dependence.  
Using the applied method it is possible to relate the position of the failed voxels to the shape of the 
radiation field, which does in fact provide some information about the clinical relevance. However, 
due to the findings in other publications, it would be interesting to evaluate the results using DVHs 
and a visualized anatomical distribution, especially for the plans with a lower pass rate. This has been 
suggested as part of future perspectives of continued work on this study. The Delta4 software has a 
complementary module, where the measured dose distribution is recalculated using the patient’s CT 
image set. The process was initiated during this thesis but due to limited time it was not possible to 
finish the implementation of the anatomical evaluation.  
Finally, the method has been in clinical use in the department in Lund for several years now. 
Extensive QA of the Linacs is done on a monthly basis, e.g. on MLC performance. This in 
combination with the daily morning checks ensures accurate beam delivery. Thus, based on their 
experience, they conclude the gamma criterion 3%, 2mm with a pass rate of at least 90%, with further 
investigation if the pass rate is below 95%, to be adequate.  
 
Based on the results of this, and previous, studies, VMAT combined with FFF-technique is realistic to 
implement at the department of Skåne University Hospital, as part of the HYPO-RT-PC study, without 
any additional work. Some of the TrueBeams are already operated in FFF-mode (6 MV) for other 
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treatments, such as stereotactic body radiotherapy for lung cancer. Introducing 10 MV FFF would 
require little effort. In the daily workflow it would imply checking the dose output for one additional 
energy, which in reality translates to approximately one or two minutes. The benefit of FFF VMAT 
for extreme hypofractionated radiotherapy is mainly the reduced treatment time, increasing patient 
comfort and possibly reducing the impact of prostate motion (which is further discussed in the next 
section). It may also be that the treatment delivery itself becomes more comparable to the conventional 
treatment if the required beam-on time is equal.  
 
6.3 THE IMPACT OF PROSTATE MOTION 
The final part of the study aimed to investigate the clinical relevance of prostate motion and what 
impact it may have on the treatment delivery. Results from previous publications emphasise the 
importance of reducing treatment time. Introducing VMAT as the main treatment technique instead of 
IMRT is one way of achieving this. However, in case of hypofractionation, the beam-on time is longer 
due to the higher absorbed dose delivered at each fraction. In this study, the treatment times are 
already shorter than in many previous trials but the hypothesis was that there may be larger 
uncertainties related to prostate displacement than necessary in the case of hypofractionated treatment 
plans using standard beams.  
 
Several studies indicate an intra-fractional continuous drift in prostate position (Lovelock et al., 2015, 
Ballhausen et al., 2015, Langen et al., 2008). In the majority of patient cases, the displacements are 
small and covered by the CTV-PTV margins. However, the effect is still important to study as in the 
cases where it does occur it may affect the outcome of the treatment, also during shorter sessions. One 
study using continuous monitoring of the prostate suggests patient repositioning if the treatment 
duration exceeds 4-6 minutes (Cramer et al., 2013). Six different motion patterns of the prostate have 
been identified (Ng et al., 2012, Kupelian et al., 2007). Using trajectory data received from Ng et al, 
the effect of these motion patterns were investigated in this thesis through the delivery of two hypo-
fractionated treatment plans, flattened and unflattened 10 MV (H10X and H10FFF, respectively). 
 
The results of the stable trajectory (ST) and the continuous drift (CD) are the same as for the static 
delivery. This is expected, considering the offsets in these trajectories being small (less than  
1 mm in the time frame of this study). This is also reassuring as the majority of patients are likely to 
exhibit this kind of motion. In the case of trajectories of persistent excursion (PE), high-frequency 
excursions (HE) and erratic behaviour (EB) the results from H10FFF are consistently better than for 
H10X; there is less difference in pass rate between H10FFF and the static delivery. The fact that the 
relative results are better for the unflattened beam is a direct effect of the shorter treatment delivery. It 
is not due to the properties of FFF beams, as it has already been shown in the previous part of the 
study that there is no significant difference in delivery or plan quality between flattened and 
unflattened 10 MV beams.  
 
These results agree with the initial expectations of the study. The shorter delivery of the H10FFF 
means that the drift in position of the prostate is smaller, which is clearly seen in Figure 21 and 24. 
The pass rate decreases faster with increased stringency on the gamma criteria for a prostate in motion 
than the static case. Hence, decreasing the treatment time is preferable in all cases but transient 
excursion (TE). A short temporal displacement constitutes a larger fraction of the total dose delivery 
for H10FFF than for H10X, and is therefore expected to result in a slightly lower relative pass rate. 
However, it is worth noting that this is purely a difference in the number of points passing the gamma 
criterion and does not give any indication about the dosimetric or radiobiological effects. It would be 
of great interest to perform a DVH evaluation and get an anatomical evaluation of the results; although 
not achievable during the course of this thesis, it would be interesting for future perspectives. 
 
Another interesting aspect is the correlation between prostate motion and rectal filling. The patients in 
the HYPO-RT-PC study are not given any instructions on emptying their rectum before treatment, but 
should be CT re-scanned if the rectum diameter exceeds 40 mm. There are studies clearly stating the 
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relation between rectal filling, causing rectal movements, and prostate intrafractional motion. The 
midpoint posterior on the prostate is the most critical point because of the rectal wall avoidance. 
Ghilezan et al. (2005) reported that for a full rectum, this anatomical point had a 10% probability of 
moving more than 3 mm in less than 1 minute compared to 20 minutes if the rectum was empty. 
Temporal displacements over 1 cm have been reported, where the motion appeared to be driven by 
peristalsis in the rectum, with a statistical significant difference observed between full and empty 
rectum (Mah et al., 2002). 
 
Furthermore, decreasing the treatment time for the hypofractionated treatment may allow for a 
decrease in CTV-PTV margins in some patients, since the uncertainty in prostatic displacement is 
limited. Decreasing margins is likely to lead to reduced toxicity. In this study the CTV-PTV margin is 
set to 7 mm isotropically. This was decided at the beginning of the HYPO-RT-PC study when imaging 
quality was poor compared to today’s techniques. Current set-up images are accurate and with daily 
verification of the prostate position it may be possible to introduce tighter margins if the treatment is 
delivered in 1 minute. For example, it has been shown that the required size of the margins is 
significantly smaller for treatment times of 2 minutes compared to 10 minutes (Shimizu et al., 2011). 
Further, the results by Gladwish et al. (2014) report less AP displacement for VMAT compared to 
fixed angle IMRT (longer treatment sessions), which they suggest is due to reduced uncertainties 
associated with random gaseous filling and emptying of rectum with reduced treatment time. Other 
studies suggest patient individual margins because of a large inter-patient spread in prostate 
displacements (Quon et al., 2012, Mutanga et al., 2011). Any conclusions about tighter margins are 
beyond the scope of this thesis project but it is an interesting aspect that should be further investigated. 
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7 CONCLUSIONS 
In conclusion, flattening filter free volumetric modulated arc therapy for extreme hypofractionated 
prostate cancer may decrease treatment times below half the time for flattened beams with the same 
prescribed dose. Using 10 MV FFF, the time required to deliver 6.1 Gy in one arc is at the minimum 
achievable value of 1.0 minute. The plan quality and the quality of delivery are equal to those of 
flattened beams. Further, the fast treatment delivery limits the intra-fractional drift of the prostate and 
is advantageous in the majority of prostate motion trajectories investigated.  
 
Finally, based on these results, it can be recommended to implement FFF VMAT for prostate cancer 
as part of the HYPO-RT-PC study at the department at Skåne University Hospital.   
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